(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
1.34% ¥ 2 300.00
Live Chart Being Loaded With Signals
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors...
Stats | |
---|---|
Volumen de hoy | 3.19M |
Volumen promedio | 2.18M |
Capitalización de mercado | 1 048.85B |
EPS | ¥0 ( 2024-01-30 ) |
Próxima fecha de ganancias | ( ¥51.38 ) 2024-05-08 |
Last Dividend | ¥37.00 ( 2023-03-30 ) |
Next Dividend | ¥0 ( N/A ) |
P/E | 8.71 |
ATR14 | ¥1.094 (0.05%) |
Volumen Correlación
Ono Pharmaceutical Co., Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ono Pharmaceutical Co., Correlación - Moneda/Commodity
Ono Pharmaceutical Co., Finanzas
Annual | 2022 |
Ingresos: | ¥447.19B |
Beneficio Bruto: | ¥337.13B (75.39 %) |
EPS: | ¥230.85 |
FY | 2022 |
Ingresos: | ¥447.19B |
Beneficio Bruto: | ¥337.13B (75.39 %) |
EPS: | ¥230.85 |
FY | 2022 |
Ingresos: | ¥361.36B |
Beneficio Bruto: | ¥267.85B (74.12 %) |
EPS: | ¥162.19 |
FY | 2021 |
Ingresos: | ¥309.28B |
Beneficio Bruto: | ¥223.71B (72.33 %) |
EPS: | ¥151.11 |
Financial Reports:
No articles found.
Ono Pharmaceutical Co., Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
¥33.00 (N/A) |
¥0 (N/A) |
¥37.00 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
¥0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | ¥6.80 | 2001-03-27 |
Last Dividend | ¥37.00 | 2023-03-30 |
Next Dividend | ¥0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 41 | -- |
Total Paid Out | ¥671.50 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.16 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.64 | |
Div. Directional Score | 9.16 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
7976.T | Ex Dividend Knight | 2023-12-28 | Semi-Annually | 0 | 0.00% | |
7212.T | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
6458.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
5464.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
4461.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
3641.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
2897.T | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
1716.T | Ex Dividend Knight | 2024-06-27 | Annually | 0 | 0.00% | |
9760.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% | |
8835.T | Ex Dividend Junior | 2024-03-28 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.256 | 1.500 | 4.88 | 7.31 | [0 - 0.5] |
returnOnAssetsTTM | 0.143 | 1.200 | 5.23 | 6.28 | [0 - 0.3] |
returnOnEquityTTM | 0.166 | 1.500 | 9.26 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.291 | -1.000 | 7.09 | -7.09 | [0 - 1] |
currentRatioTTM | 3.95 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 3.19 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 1.140 | 1.500 | 4.78 | 7.17 | [0.2 - 2] |
debtRatioTTM | 0.00963 | -1.500 | 9.84 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 99.03 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | 222.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 191.88 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0109 | -1.500 | 9.96 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.756 | 1.000 | 0.740 | 0.740 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.329 | 1.000 | 5.41 | 5.41 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 12.35 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.559 | 0.800 | 9.61 | 7.69 | [0.5 - 2] |
Total Score | 12.67 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.58 | 1.000 | 9.23 | 0 | [1 - 100] |
returnOnEquityTTM | 0.166 | 2.50 | 9.53 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 191.88 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.48 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 222.86 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.291 | 1.500 | 7.09 | -7.09 | [0 - 1] |
pegRatioTTM | -1.449 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.213 | 1.000 | 7.18 | 0 | [0.1 - 0.5] |
Total Score | 5.64 |
Ono Pharmaceutical Co.,
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico